Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...
Adjusted EBITDA -- $30 million, more than doubling from $14 million, attributed to operational improvements, acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results